hit counter

SDQ Had the Strongest Evidence Among Broad ADHD Rating Scales for Children

MHD card with a glowing amber clipboard holding a rating questionnaire with filled answer bubbles, over a faint grid of checkmarks and crosses on a dark background, illustrating a review of ADHD rating scales for children.

Among broad child behavior questionnaires used to screen for ADHD, the short hyperactivity-inattention subscale of the Strengths and Difficulties Questionnaire (SDQ) has the strongest measurement evidence, according to a 2026 review of 36 studies. None of the 12 scales reviewed met every quality standard.1 Research Highlights 36 studies, 12 scales: a systematic review in BMC …

Read more

Bumetanide PROMset Study: 83% Improved in 1 Sensory-Related Domain

MHD featured image for bumetanide and sensory-related parent-reported outcomes in neurodevelopmental disorders.

A 2026 medRxiv preprint using parent-cocreated sensory-related outcome measures found that 83% of children and teens improved on at least 1 PROMIS domain during 6 months of bumetanide treatment.1 The result is interesting, but the unmasked single-case design means the strongest claim is about sensitive outcome tracking, not definitive bumetanide efficacy. Research Highlights Most participants …

Read more

Autism vs. ADHD Connectome Study: Frontal-DMN Signal Tracks Autism Severity

MHD featured image for autism, ADHD, and connectome-based symptom mapping.

A 166-child resting-state fMRI study found that clinician-observed autism severity, not ADHD severity, tracked connectivity strength between a left middle frontal gyrus node and the posterior cingulate/default mode network across children diagnosed with autism or ADHD without autism. The result is transdiagnostic, but asymmetrical: autism traits carried the connectome signal after ADHD ratings were controlled.1 …

Read more

Levetiracetam Range in Children: 2.82-24.37 mcg/mL TDM

MHD featured image for levetiracetam therapeutic drug monitoring in children with epilepsy.

A 2026 real-world study involving 1,174 children with epilepsy proposed a levetiracetam therapeutic drug monitoring range of 2.82-24.37 mcg/mL, much lower than commonly cited adult-style ranges, but the same data also warned against treating a drug level as a stand-alone seizure-control predictor. Research Highlights Lower pediatric range: Sun et al. proposed an observational levetiracetam range …

Read more